Flotetuzumab 用于难治性急性髓系白血病的挽救性免疫治疗
约50%的急性髓系白血病(AML)患者对诱导治疗无反应(原发诱导失败[PIF])或缓解后6个月内复发(早期复发[ER])。本文报告一项多中心、开放标签、1/2期研究,评估CD3ε/CD123双特异性DART抗体flotetuzumab在88例复发/难治性AML成人中的安全性和活性。在推荐2期剂量(RP2D)500 ng/kg/天下治疗的30例PIF/ER患者中,完全缓解(CR)/部分血液学恢复的CR(CRh)率为26.7%,总缓解率为30.0%。
要点
- flotetuzumab在PIF/ER患者中显示出可接受的安全性和鼓舞人心的活性证据。
- RP2D为500 ng/kg/天,最常见不良事件为输注相关反应/细胞因子释放综合征,多为1-2级。
- 骨髓转录组10基因特征可预测flotetuzumab的CR,AUC=0.904,优于ELN分类器的0.672。
核心结论
- Flotetuzumab是一种创新的实验性方法,在PIF/ER患者中安全性可接受且活性证据令人鼓舞。
研究设计与样本
- 多中心、开放标签、1/2期研究,纳入88例复发/难治性AML成人,42例在剂量探索阶段,46例在RP2D 500 ng/kg/天阶段。
主要发现
- 最常见不良事件为输注相关反应/细胞因子释放综合征,大多为1-2级。
- 第1周阶梯剂量、预处理地塞米松、及时使用托珠单抗及暂时减量/中断成功预防了严重IRR/CRS。
- 在RP2D治疗的30例PIF/ER患者中,CR/CRh率为26.7%,总缓解率(CR/CRh/CRi)为30.0%。
- 达到CR/CRh的PIF/ER患者中位OS为10.2个月(范围1.87-27.27),6个月和12个月生存率分别为75%(95%CI 0.450-1.05)和50%(95%CI 0.154-0.846)。
- 骨髓转录组分析显示简约10基因特征预测flotetuzumab的CR(AUC=0.904 vs ELN分类器0.672)。
关键数值与推荐
- RP2D为500 ng/kg/天。
- RP2D治疗的30例PIF/ER患者中CR/CRh率为26.7%,总缓解率为30.0%。
- 达到CR/CRh的PIF/ER患者中位OS为10.2个月(范围1.87-27.27),6个月和12个月生存率分别为75%(95%CI 0.450-1.05)和50%(95%CI 0.154-0.846)。
- 10基因特征预测CR的AUC=0.904,ELN分类器AUC=0.672。
临床怎么用
- 对于PIF/ER的AML患者,flotetuzumab提供了一种具有可接受安全性和初步疗效的挽救性免疫治疗选择。
- 采用第1周阶梯剂量、预处理地塞米松、及时使用托珠单抗及暂时减量/中断可预防严重IRR/CRS。
- 骨髓转录组10基因特征可能有助于筛选可能从flotetuzumab治疗中获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after <6 months (early relapse [ER]). We have recently shown an association between an immune-infiltrated tumor microenvironment (TME) and resistance to cytarabine-based chemotherapy but responsiveness to flotetuzumab, a bispecific DART antibody-based molecule to CD3ε and CD123. This paper reports the results of a multicenter, open-label, phase 1/2 study of flotetuzumab in 88 adults with relapsed/refractory AML: 42 in a dose-finding segment and 46 at the recommended phase 2 dose (RP2D) of 500 ng/kg per day. The most frequent adverse events were infusion-related reactions (IRRs)/cytokine release syndrome (CRS), largely grade 1-2. Stepwise dosing during week 1, pretreatment dexamethasone, prompt use of tocilizumab, and temporary dose reductions/interruptions successfully prevented severe IRR/CRS. Clinical benefit accrued to PIF/ER patients showing an immune-infiltrated TME. Among 30 PIF/ER patients treated at the RP2D, the complete remission (CR)/CR with partial hematological recovery (CRh) rate was 26.7%, with an overall response rate (CR/CRh/CR with incomplete hematological recovery) of 30.0%. In PIF/ER patients who achieved CR/CRh, median overall survival was 10.2 months (range, 1.87-27.27), with 6- and 12-month survival rates of 75% (95% confidence interval [CI], 0.450-1.05) and 50% (95% CI, 0.154-0.846). Bone marrow transcriptomic analysis showed that a parsimonious 10-gene signature predicted CRs to flotetuzumab (area under the receiver operating characteristic curve = 0.904 vs 0.672 for the European LeukemiaNet classifier). Flotetuzumab represents an innovative experimental approach associated with acceptable safety and encouraging evidence of activity in PIF/ER patients. This trial was registered at www.clinicaltrials.gov as #NCT02152956.
引用
- Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021. PMID: 32929488. doi:10.1182/blood.2020007732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。